Munich – The biosimilars company Formycon is underpinning its claim to scientific excellence by appointing Johannes Buchner, professor in Biotechnology at the Technische Universität München (Technical University of Munich) and President of the German Society for Biochemistry and Molecular Biology (GBM), to its Advisory Board. Professor Buchner is a globally recognized expert in biotechnological research and development.

After studying Biology and receiving his PhD from the University of Regensburg in 1991, Buchner investigated new concepts in cancer treatment during his postdoctoral stay at the National Institutes of Health in Bethesda, USA. He returned to the University of Regensburg as a group leader, and since 1998 he is a Professor for Biotechnology at the Technische Universität München, Germany. His research focuses on chaperone proteins and antibodies. Buchner is a member of the German Academy of Sciences (Leopoldina) as well as the Bavarian Academy of Sciences and Humanities. He has received numerous awards for his research, including the Hans Neurath Award from the Protein Society and the Schleiden Medal awarded by Leopoldina.

“I am delighted that we have been able to welcome Professor Johannes Buchner, a highly renowned professional in the field of molecular biology and antibody research. His expertise will play a significant role in our Advisory Board and will support our development work”, comments Dr. Carsten Brockmeyer, CEO of Formycon AG.

In addition to Professor Buchner, the board consists of Dr. Gerhard Schaefer und Dr. Bernhard Hampl, who are both highly experienced managers and proven industry experts from the pharmaceutical sector.